Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors

REFERENCES

• Sainsbury J. R., Farndon J. R., Needham G. K., et al. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1: 1398–1402
   PubMed Web of Science ®Google Scholar
• Gibault L., Metges J. P., Conan-Charlet V., et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br. J. Cancer 2005; 93: 107–115
   PubMed Web of Science ®Google Scholar
• Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003; 21: 2237–2246
   PubMed Web of Science ®Google Scholar
• Kris M. G., Natale R. B., Herbst R. S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149–2158
   PubMed Web of Science ®Google Scholar
• Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin. Lung Cancer 2004; 6: S20–S23, (Suppl. 1)
   PubMedGoogle Scholar
• Shepherd F. A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353: 123–132
   PubMed Web of Science ®Google Scholar
• Thatcher N., Chang A., Parikh P., et al. Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care in patients with advanced non-small cell lung cancer who had received 1 or 2 prior chemotherapy regimens. Proc. Am. Assoc. Cancer Res. Late Breaking Session 2005
   Google Scholar
• Giaccone G., Herbst R. S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J. Clin. Oncol. 2004; 22: 777–784
   PubMed Web of Science ®Google Scholar
• Herbst R. S., Giaccone G., Schiller J. H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J. Clin. Oncol. 2004; 22: 785–794
   PubMed Web of Science ®Google Scholar
• Herbst R. S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005; 23: 5892–5899
   PubMed Web of Science ®Google Scholar
• Gatzemeier U. P., Szczesna A. Results of a phase III trial of erlotinib combined with cisplatin and gemcitabine Chemotherapy in Advanced Non-Small Cell Lung Cancer. JCO 2004; 22(14S), Abs 7010
   Google Scholar
• Paez J. G., Janne P. A., Lee J. C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500
   PubMed Web of Science ®Google Scholar
• Takano T., Ohe Y., Sakamoto H., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005; 23: 6829–6837
   PubMed Web of Science ®Google Scholar
• Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2001; 101: 13306–13311
   Google Scholar
• Bell D. W., Lynch T. J., Haserlat S. M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005; 23: 8081–8092
   PubMed Web of Science ®Google Scholar
• Grunwald V., Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. 2003; 95: 851–867
   PubMed Web of Science ®Google Scholar
• Lee J. W., Soung Y. H., Kim S. Y., et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2005; 11: 2879–2882
   PubMed Web of Science ®Google Scholar
• Nagahara H., Mimori K., Ohta M., et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin. Cancer Res. 2005; 11: 1368–1371
   PubMed Web of Science ®Google Scholar
• Hanawa M., Suzuki S., Dobashi Y., et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 2005; 118: 1173–1180
   Web of Science ®Google Scholar
• Xie D., Zeng Y. X., Wang H. J., et al. Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway. Acta Neuropathol. (Berl.) 2005; 110: 481–489
   PubMed Web of Science ®Google Scholar
• Haas-Kogan D. A., Prados M. D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 2005; 97: 880–887
   PubMed Web of Science ®Google Scholar
• Wheeler R. H., Jones D., Sharma P., et al. Clinical and molecular phase II study of gefitinib in patients with recurrent squamous cell cancer of the head and neck. JCO 2005; 23(165), Abs 5531
   Google Scholar
• Adelstein D. J., Rybicki L. A., Carroll M. A., et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction cancer. JCO 2005; 23(165), Abs 4054
   Google Scholar
• Polychronis A., Sinnett H. D., Hadjiminas D., et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005; 6: 383–391
   PubMed Web of Science ®Google Scholar
• Robertson J. F.R., Gutteridge E., Cheung K. L., et al. Gefitinib is active in acquired tamoxifen-resistant oestrogen receptor-positive and ER-negative breast cancer: results from a phase II study. JCO, 22(14S), Abs 23
   Google Scholar
• Hutcheson I. R., Knowlden J. M., Madden T. A., et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. Treat. 2003; 81: 81–93
   PubMed Web of Science ®Google Scholar
• Moore M. J.G.D., Hamm J., Kotecha J., Gallinger S., Au H. J., Nomikos D., Ding K., Ptaszynski M., Parulekar W. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proceedings from ASCO Gastrointestinal Cancers Symposium. 2005, Abs 77
   Google Scholar
• Slamon D. J., Clark G. M., Wong S. G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• DiGiovanna M. P., Stern D. F., Edgerton S. M., et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol. 2005; 23: 1152–1160
   PubMed Web of Science ®Google Scholar
• Moulder S. L., Yakes F. M., Muthuswamy S. K., et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001; 61: 8887–8895
   PubMed Web of Science ®Google Scholar
• Johnston S. R., Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006; 42: 441–453
   PubMed Web of Science ®Google Scholar
• Burris H. A., 3rd, Hurwitz H. I., Dees E. C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005; 23: 5305–5313
   PubMed Web of Science ®Google Scholar
• Gomez H. C. M., Doval D., Nag S., Chow L., Ang P. C., Ahmad N. M., Berger M., Newstat B., Stein S., Sledge G. Biomarker results from a phase II randomized study of lapatinib as first line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer. Breast Can Res Treat, 94(s1), Abs 1071
   PubMedGoogle Scholar
• Blackwell K. B. H., Pegram M., Storniolo A., Salazar V., Maleski J., Lin X., Spector N., Stein S., Berger M. Determining Relevant Biomarkers from Tissue and Serum that May Predict Response to Single Agent Lapatinib in Trastuzumab Refractory Metastatic Breast Cancer. JCO 2005; 23(16S), Abs 3004
   Google Scholar
• Geyer C. E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. Dec 28, 2006; 355(26)2733–2743
   PubMed Web of Science ®Google Scholar
• Allen L. F., Eiseman I. A., Fry D. W., et al. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol. 2003; 30: 65–78
   PubMed Web of Science ®Google Scholar
• Campos S., Hamid O., Seiden M. V., et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J. Clin. Oncol. 2005; 23: 5597–5604
   PubMed Web of Science ®Google Scholar
• Hellawell G. O., Turner G. D., Davies D. R., et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002; 62: 2942–2950
   PubMed Web of Science ®Google Scholar
• Zhang X., Lin M., van Golen K. L., et al. Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration. Breast Cancer Res Treat. 2005; 93: 159–168
   PubMed Web of Science ®Google Scholar
• Sachdev D., Hartell J. S., Lee A. V., et al. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004; 279: 5017–5024
   PubMed Web of Science ®Google Scholar
• Jones H. E., Goddard L., Gee J. M., et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11: 793–814
   PubMed Web of Science ®Google Scholar
• Zhang X., Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 2002; 62: 4369–4375
   PubMed Web of Science ®Google Scholar
• Scotlandi K., Manara M. C., Nicoletti G., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65: 3868–3876
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C., Pearson M. A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231–239
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15–18
   PubMed Web of Science ®Google Scholar
• Miller K. D., Chap L. I., Holmes F. A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005; 23: 792–799
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Mross K., Drevs J., Muller M., et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005; 41: 1291–1299
   PubMed Web of Science ®Google Scholar
• Hecht J. T. T., Jaeger E., Hainsworth J., Wolff R., Lloyd K., Bodoky G., Borner M., Laurent D., Jacques C. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK/ZK 222584 or placebo (CONFIRM-1). JCO 2005; 23(16S), Abs 3
   Google Scholar
• Drevs J., Medinger M., Moss K., et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. JCO 2005; 23(S16), Abs 3002
   Google Scholar
• Motzer R. R.B., Michaelson M., Redman B., Hudes G., Wilding G., Bukowski R., George D., Kim S., Baum C. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. ASCO 2005
   Google Scholar
• Motzer R., Hutson T., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell cancer. NEJM, 2007; 356: 115–124
   PubMed Web of Science ®Google Scholar
• Demetri G. D., Van Oosterom A. T., Garett G. R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumours after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329–1338
   PubMed Web of Science ®Google Scholar
• Rugo H. S., Herbst R. S., Liu G., , Phase I, et al. trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 2005; 23: 5474–5483
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Dowlati A., Savage S., et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. JCO 2005; 23(16S), Abs 3012
   Google Scholar
• Yigitbasi O. G., Younes M. N., Doan D., et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004; 64: 7977–7984
   PubMed Web of Science ®Google Scholar
• Martinelli E., Takimoto C., van Oosterom A., et al. AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family 1335 tyrosine kinases: preliminary phase I results. JCO 2005; 23(16S)
   Google Scholar
• Miettinen M., Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12
   PubMed Web of Science ®Google Scholar
• Emile J. F., Theou N., Tabone S., et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004; 2: 597–605
   PubMed Web of Science ®Google Scholar
• Demetri G. D., von Mehren M., Blanke C. D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480
   PubMed Web of Science ®Google Scholar
• Heinrich M. C., Corless C. L., Demetri G. D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21: 4342–4349
   PubMed Web of Science ®Google Scholar
• Hotte S. J., Winquist E. W., Lamont E., et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J. Clin. Oncol. 2005; 23: 585–590
   PubMed Web of Science ®Google Scholar
• Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005
   PubMed Web of Science ®Google Scholar
• Gotlib J., Cross N. C., Gilliland D. G. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 2006; 19: 535–569
   PubMed Web of Science ®Google Scholar
• Beeram M., Patnaik A., Rowinsky E. K. Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol. 2005; 23: 6771–6790
   PubMed Web of Science ®Google Scholar
• Bos J. L. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–4689
   PubMed Web of Science ®Google Scholar
• Karp J. E., Lancet J. E. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies. Ann Hematol 2004; 83: S87–S88, (Suppl 1)
   PubMedGoogle Scholar
• Johnston S. R., Hickish T., Ellis P., , Phase I I, et al. study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. 2003; 21: 2492–2499
   PubMed Web of Science ®Google Scholar
• Rao S., Cunningham D., de Gramont A., et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 2004; 22: 3950–3957
   PubMed Web of Science ®Google Scholar
• Van Cutsem E., Van de Velde H., Karasek P., Oettle H., Vervenne W. L., Szawlowski A. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. JCO 2004; 22: 1430–1438
   PubMed Web of Science ®Google Scholar
• Du W., Prendergast G. C. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 1999; 59: 5492–5496
   PubMed Web of Science ®Google Scholar
• Appels N. M., Beijnen J. H., Schellens J. H. Development of farnesyl transferase inhibitors: a review. Oncologist 2005; 10: 565–578
   PubMed Web of Science ®Google Scholar
• Martin N. E., Brunner T. B., Kiel K. D., et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 2004; 10: 5447–5454
   PubMed Web of Science ®Google Scholar
• Ellis C. A., Vos M. D., Wickline M., et al. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 2003; 78: 59–67
   PubMed Web of Science ®Google Scholar
• Davies H., Bignell G. R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954
   PubMed Web of Science ®Google Scholar
• Flaherty K. B. M., Schuchter L., Tuveson D., Lee R., Schwartz B., Lathia C., Weber B., O'Dwyer P. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. ASCO 2004
   Google Scholar
• Eisen T., Ahmad T., Gore M., Marais R., Gibbens I., James M., Schwartz B., Bergamini L. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. JCO 2005; 23(14S), Abs 7508
   Google Scholar
• Escudier B., Eisen T., Stadler W. M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125–134
   PubMed Web of Science ®Google Scholar
• Foster K., Prowse A., van den Berg A., et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994; 3: 2169–2173
   PubMed Web of Science ®Google Scholar
• Gnarra J. R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85–90
   PubMed Web of Science ®Google Scholar
• Herman J. G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700–9704
   PubMed Web of Science ®Google Scholar
• Lonergan K. M., Iliopoulos O., Ohh M., et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998; 18: 732–741
   PubMed Web of Science ®Google Scholar
• Iliopoulos O., Levy A. P., Jiang C., et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10595–10599
   PubMed Web of Science ®Google Scholar
• Rinehart J., Adjei A. A., Lorusso P. M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004; 22: 4456–4462
   PubMed Web of Science ®Google Scholar
• Janus A., Robak T., Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005; 10: 479–498
   PubMed Web of Science ®Google Scholar
• Samuels Y., Velculescu V. E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221–1224
   PubMed Web of Science ®Google Scholar
• Leslie N. R., Downes C. P. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004; 382: 1–11
   PubMed Web of Science ®Google Scholar
• Bondar V. M., Sweeney-Gotsch B., Andreeff M., et al. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989–997
   PubMed Web of Science ®Google Scholar
• Hu L., Hofmann J., Lu Y., et al. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087–1092
   PubMed Web of Science ®Google Scholar
• Dutcher J. P. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004; 10: 6382S–63857S
   PubMed Web of Science ®Google Scholar
• Atkins M. B., Hidalgo M., Stadler W. M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 2004; 22: 909–918
   PubMed Web of Science ®Google Scholar
• Chan S., Scheulen M. E., Johnston S., , Phase I I, et al. study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2005; 23: 5314–5322
   PubMed Web of Science ®Google Scholar
• Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271–2281
   PubMed Web of Science ®Google Scholar
• Yu K., Toral-Barza L., Discafani C., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249–258
   PubMed Web of Science ®Google Scholar
• Nam S., Kim D., Cheng J. Q., et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185–9189
   PubMed Web of Science ®Google Scholar
• Wiener J. R., Windham T. C., Estrella V. C., , Activated S RC, et al. protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003; 88: 73–79
   PubMed Web of Science ®Google Scholar
• Johnson F. M., Saigal B., Talpaz M., et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924–6932
   PubMed Web of Science ®Google Scholar
• Yezhelyev M. V., Koehl G., Guba M., et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004; 10: 8028–8036
   PubMed Web of Science ®Google Scholar
• Talpaz M., Shah NP., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–25341
   PubMed Web of Science ®Google Scholar
• Shapiro G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006; 24: 1770–1783
   PubMed Web of Science ®Google Scholar
• Tan A. R., Headlee D., Messmann R., , Phase I, et al. clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J. Clin. Oncol. 2002; 20: 4074–4082
   PubMed Web of Science ®Google Scholar
• Grendys E. C., Jr., Blessing J. A., Burger R., et al. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 98: 249–253
   PubMed Web of Science ®Google Scholar
• Shah M. A., Kortmansky J., Motwani M., et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11: 3836–3845
   PubMed Web of Science ®Google Scholar
• Tan A. R., Yang X., Berman A., , Phase I, et al. trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004; 10: 5038–5047
   PubMed Web of Science ®Google Scholar
• Patel V., Lahusen T., Leethanakul C., et al. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 2002; 8: 3549–3560
   PubMed Web of Science ®Google Scholar
• Sausville E. A., Arbuck S. G., Messmann R., , Phase I, et al. trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 2001; 19: 2319–2333
   PubMed Web of Science ®Google Scholar
• Lara P. N., Jr., Mack P. C., Synold T., et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005; 11: 4444–4450
   PubMed Web of Science ®Google Scholar
• Smyth J. F., Aamdal S., Awada A., , Phase I I, et al. study of E7070 in patients with metastatic melanoma. Ann Oncol 2005; 16: 158–161
   PubMed Web of Science ®Google Scholar
• Blagden S., de Bono J. Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 2005; 6: 325–335
   PubMed Web of Science ®Google Scholar
• Hartson S. D., Matts R. L. Association of Hsp90 with cellular Src-family kinases in a cell-free system correlates with altered kinase structure and function. Biochemistry 1994; 33: 8912–8920
   PubMed Web of Science ®Google Scholar
• da Rocha Dias S., Friedlos F., Light Y., et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65: 10686–10691
   PubMed Web of Science ®Google Scholar
• Solit D. B., Zheng F. F., Drobnjak M., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8: 986–993
   PubMed Web of Science ®Google Scholar
• Gossett D. R., Bradley M. S., Jin X., et al. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. Gynecol Oncol 2005; 96: 381–388
   PubMed Web of Science ®Google Scholar
• Bisht K. S., Bradbury C. M., Mattson D., et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003; 63: 8984–8995
   PubMed Web of Science ®Google Scholar
• Nguyen D. M., Lorang D., Chen G. A., et al. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001; 72: 371–378, discussion 378–379
   PubMed Web of Science ®Google Scholar
• Smith V., Sausville E. A., Camalier R. F., et al. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005; 56: 126–137
   PubMed Web of Science ®Google Scholar
• Caravita T., de Fabritiis P., Palumbo A., et al. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006; 3: 374–387
   PubMedGoogle Scholar
• Richardson P. G., Hideshima T., Anderson K. C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003; 10: 361–369
   PubMedGoogle Scholar
• Richardson P. G., Sonneveld P., Schuster M. W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Horvath C. M., Darnell J. E. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol 1997; 9: 233–239
   PubMed Web of Science ®Google Scholar
• Xu Q., Briggs J., Park S., et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24: 5552–5560
   PubMed Web of Science ®Google Scholar
• Baus D., Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer 2005
   Web of Science ®Google Scholar
• Faderl S., Ferrajoli A., Harris D., et al. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res 2005; 25: 1841–18450
   PubMed Web of Science ®Google Scholar
• Insinga A., Monestiroli S., Ronzoni S., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71–76
   PubMed Web of Science ®Google Scholar
• Vrana J. A., Decker R. H., Johnson C. R., et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18: 7016–7025
   PubMed Web of Science ®Google Scholar
• Saito A., Yamashita T., Mariko Y., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592–4597
   PubMed Web of Science ®Google Scholar
• Kelly W. K., O'Connor O. A., Krug L. M., , Phase I, et al. study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005; 23: 3923–3931
   PubMed Web of Science ®Google Scholar
• Ryan Q. C., Headlee D., Acharya M., , Phase I, et al. and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005; 23: 3912–322
   PubMed Web of Science ®Google Scholar
• Sandor V., Bakke S., Robey RW., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718–728
   PubMed Web of Science ®Google Scholar
• Silverman L. R., Mufti G. J. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2005; 2: S12–S23, (Suppl 1)
   Google Scholar
• Kojima K., Konopleva M., Samudio I. J., et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150–3159
   PubMed Web of Science ®Google Scholar
• Schimmer A. D., Welsh K., Pinilla C., et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25–35
   PubMed Web of Science ®Google Scholar
• Sapi E., Alvero A. B., Chen W., et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004; 14: 567–578
   PubMed Web of Science ®Google Scholar
• Rutherford T. O.M.D., Makkenchery A., Baker L., Azodi M., Schwartz P., Mor G. Phenoxodiol Phase Ib/II Study in Patients with Recurrent Ovarian Cancer that are Resistant to > Second Line Chemotherapy. Proc. Am. Assoc. Cancer Res. 2004
   Google Scholar
• Shih Y. N., Chiu C. H., Tsai C. M., et al. Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. J Chin Med Assoc 2005; 68: 183–186
   PubMedGoogle Scholar
• Barnes C. J., Bagheri-Yarmand R., Mandal M., et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2: 345–351
   PubMed Web of Science ®Google Scholar
• Xia W., Mullin R. J., Keith B. R., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255–6263
   PubMed Web of Science ®Google Scholar
• Spector N. L., Xia W., Burris H., 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 2005; 23: 2502–2512
   PubMed Web of Science ®Google Scholar
• Tan A. R., Yang X., Hewitt S. M., et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 2004; 22: 3080–3090
   PubMed Web of Science ®Google Scholar
• Liu G., Rugo H. S., Wilding G., et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol. 2005; 23: 5464–5473
   PubMed Web of Science ®Google Scholar
• Jager P. L., Gietema J. A., van der Graaf W. T. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004; 25: 433–438
   PubMed Web of Science ®Google Scholar
• Ratain M., Eisen T., Stadler W., Flaherty K. T., Kaye S. B., Rosner G. L., , Phase I I, et al. placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. JCO, 2006; 24: 2505–2512
   PubMed Web of Science ®Google Scholar
• Guix M. K. S., Reyzer M., Zhang J., Shyr Y., McLaren B., Newsome-Johnson K., Lipscomb W., Dugger T., Arteaga C. Short Course of EGF Receptor Tyrosine Kinase Inhibitor Erlotinib Reduces Tumor Cell Proliferation and Active MAP Kinase in Situ in Untreated Operable Breast Cancers: A Strategy for patient Selection into Phase II Trials with Signaling Inhibitors. ASCO 2005
   Google Scholar
• Nicholson R. I., McClelland R. A., Robertson J. F., et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373–387
   PubMed Web of Science ®Google Scholar
• Schiff R., Massarweh S. A., Shou J., et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004; 10: 331S–336S
   PubMed Web of Science ®Google Scholar
• Gee J. M., Harper M. E., Hutcheson I. R., et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003; 144: 5105–5117
   PubMed Web of Science ®Google Scholar
• Chu I., Blackwell K., Chen S., et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005; 65: 18–25
   PubMed Web of Science ®Google Scholar
• Doisneau-Sixou S. F., Cestac P., Faye J. C., et al. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 2003; 106: 789–798
   PubMed Web of Science ®Google Scholar
• Chow L. W.C., Shun Y., Jassem J., et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Can Res Treat, 100(S1), Abs 6091
   Google Scholar
• Lu Y., Zi X., Zhao Y., et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852–1857
   PubMed Web of Science ®Google Scholar
• Sini P., Wyder L., Schnell C., et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 2005; 11: 4521–432
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Sosman J. A., Spigel D. R., et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). J. Clin. Oncol. (Meeting Abstracts) 2004; 22: 4502
   Google Scholar
• Kokubo Y., Gemma A., Noro R., et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005; 92: 1711–1719
   PubMed Web of Science ®Google Scholar
• She Q. B., Solit D., Basso A., et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003; 9: 4340–4346
   PubMed Web of Science ®Google Scholar
• Burchert A., Wang Y., Cai D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005; 19: 1774–1782
   PubMed Web of Science ®Google Scholar
• Huang S., Armstrong E. A., Benavente S., et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64: 5355–5362
   PubMed Web of Science ®Google Scholar
• Xia W., Gerard C. M., Liu L., et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24: 6213–6221
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792
   PubMed Web of Science ®Google Scholar
• Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345
   PubMed Web of Science ®Google Scholar
• Raben D., Helfrich B. A., Chan D., et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002; 29: 37–46
   PubMed Web of Science ®Google Scholar
• Van Cutsem E., van de Velde H., Karasek P., , Phase I II, et al. trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004; 22: 1430–1438
   PubMed Web of Science ®Google Scholar
• Eberhard D. A., Johnson B. E., Amler L. C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 2005; 23: 5900–5909
   PubMed Web of Science ®Google Scholar
• Braun S., Pantel K., Muller P., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 2000; 342: 525–533
   PubMed Web of Science ®Google Scholar
• Pantel K., Schlimok G., Braun S., et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl. Cancer Inst. 1993; 85: 1419–1424
   PubMed Web of Science ®Google Scholar
• Stathopoulou A., Vlachonikolis I., Mavroudis D., et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 2002; 20: 3404–3412
   PubMed Web of Science ®Google Scholar
• Braun S., Kentenich C., Janni W., et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 2000; 18: 80–86
   PubMed Web of Science ®Google Scholar
• Bozionellou V., Mavroudis D., Perraki M., et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. lin Cancer Res 2004; 10: 8185–8194
   Web of Science ®Google Scholar
• Romond E. H., Perez E. A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684
   PubMed Web of Science ®Google Scholar
• Galanis E. B.J., Maurer M., Hidalgo M., Kreisberg J., Peralba J., Jenkins R., Walsh D. N997B: Phase II Trial of CCI-779 in Recurrent Glioblastoma Multiforme: Updated Results and Correlative Laboratory Analysis. JCO 2005; 23(s16), Abs 1505
   Google Scholar
• Pandya K. L. D., Hidalgo M., Cohen R., Lee M., Schiller J., Johnson D. A Randomized, Phase II ECOG Trial of Two Dose Levels of Temsirolimus in Patients with Extensive Stage Small Cell Lung Cancer in Remission after Induction Chemotherapy. A Preliminary Report. JCO 2005; 23(s16), Abs 7005
   Google Scholar
• Duran I. L.L., Saltman D., Kortmansky J., Kocha W., Singh D., Pond G., Peralba J., Dancey J., Siu L. A Phase II Trial of Temsirolimus in Metastatic Neuroendocrine Carcinomas. JCO 2005; 23(s16), Abs 3096
   Google Scholar
• Milton D. K.M., Azzoli C., Gomez J., Heelan R., Krug L., Pao W., Pizzo B., Rizvi N., Miller V. Phase I/II Trial of Gefitinib and RAD001 in Patients with Advanced Non-Small Cell Lung Cancer. JCO 2005; 23(s16), Abs 7104
   Google Scholar
• Van Oosterom A. D.H., Desai J., Stroobants S., Van Den Abbeele A., Clement P., Shand N., Kovarik J., Tsyrlova A., Demetri G. Combination Signal Transduction Inhibition: A Phase I/II Trial of the Oral mTOR-Inhibitor Everolimus and Imatinib Mesylate (IM) in Patients with Gastrointestinal Stromal Tumor Refractory to IM. ASCO Proc 2004
   Google Scholar
• Chow L. W., Sun Y., Jassem J., et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Can Res Treat 2006; 100(S1), Abs 6091
   Google Scholar